RxDoctor Payments Data

John Opilka, DO

Family Medicine · Altamont, ILNPI 1497715056

Payments from drug & device makers

$1,190in general payments, 2019–2025

Across 78 payments — averaging $15.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$444
  • Amgen$153
  • AbbVie$127
  • Johnson & Johnson$120
  • Lilly USA, LLC$62
  • AstraZeneca$59
  • plus $225 from 9 others

What the payments were for

  • Food & beverage$1,15297%
  • Education$393%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,190 in reported general payments places this provider in the 75th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$374,745
Medicare patients
613
Services billed
4,674

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban483$233,783
JardianceEmpagliflozin66$50,154
OzempicSemaglutide36$35,055
XareltoRivaroxaban57$27,432
JanuviaSitagliptin Phosphate31$20,383
XifaxanRifaximin11$17,758
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$14,812
EntrestoSacubitril/Valsartan29$14,496
Memantine Hcl230$12,889
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$12,654
RexultiBrexpiprazole16$11,337
TradjentaLinagliptin16$9,788
Potassium Chloride528$9,563
CreonLipase/Protease/Amylase23$8,031
NamzaricMemantine Hcl/Donepezil Hcl26$7,844

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$33$241,331506 claims
Novo NordiskOzempic$444$35,05536 claims
Johnson & JohnsonXarelto$120$27,43257 claims
AstraZenecaBreztri Aerosphere, Farxiga$59$22,38241 claims
GSKTrelegy Ellipta, Incruse Ellipta$35$16,78432 claims
AbbVieCreon, Namzaric$127$15,87449 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Altamont

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →